{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:09:47Z","timestamp":1790730587667,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The efficacy and safety of low\u2010dose anti\u2010PD1 antibodies in relapsed\/refractory classical Hodgkin lymphoma (cHL) require confirmation. Pembrolizumab (100 mg every 3 weeks, Q3W) or nivolumab (40 mg Q2W) were administered to patients with relapsed\/refractory cHL. In the pembrolizumab cohort (\n                    <jats:italic>N<\/jats:italic>\n                    = 11), who had failed a median of three (1\u20136) therapies (brentuximab vedotin [BV]: 91%; autologous hematopoietic stem cell transplantation [auto\u2010HSCT]: 18%), the overall response rate (ORR) by positron emission tomography\u2013computed tomography was 100% (metabolic complete response [mCR]: 73%; partial response [PR]: 27%). Median cumulative dose for achieving best response was 400 (300\u2013800) mg. Median progression\u2010free survival (PFS) was 35 months. Median overall survival (OS) was not reached. Adverse events (AEs) of grade 1\u20132 were observed in three patients. In the nivolumab cohort (\n                    <jats:italic>N<\/jats:italic>\n                    = 6), who had failed a median of three (2\u20136) therapies (BV: 50%; auto\u2010HSCT: 17%; allogeneic HSCT: 34%), the ORR was 100% (mCR: 67%; PR: 17%; indeterminate response: 17%). Median cumulative dose for achieving best response was 160 (160\u2013360) mg. Median PFS was 33 months. Median OS was not reached. AEs of grade 1\u20132 were observed in four patients, two of whom had pre\u2010existing autoimmune conditions. Five patients with Epstein\u2013Barr virus (EBV) positive Reed\u2013Sternberg cells underwent monitoring of plasma EBV DNA, which became negative in four mCR patients but remained positive in one PR patient who died ultimately from refractory lymphoma. Low\u2010dose pembrolizumab and nivolumab were highly efficacious and safe in relapsed\/refractory cHL. These observations have significant financial implications in resource\u2010constrained settings.\n                  <\/jats:p>","DOI":"10.1002\/hon.2787","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T23:02:13Z","timestamp":1597273333000},"page":"726-736","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Low\u2010dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource\u2010constrained setting"],"prefix":"10.1002","volume":"38","author":[{"given":"Thomas S. Y.","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Medicine Queen Mary Hospital  Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Yan","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Medicine Queen Mary Hospital  Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pek\u2010Lan","family":"Khong","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology Queen Mary Hospital  Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anskar Y. H.","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Medicine Queen Mary Hospital  Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2427-915X","authenticated-orcid":false,"given":"Chor\u2010Sang","family":"Chim","sequence":"additional","affiliation":[{"name":"Department of Medicine Queen Mary Hospital  Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric W. C.","family":"Tse","sequence":"additional","affiliation":[{"name":"Department of Medicine Queen Mary Hospital  Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8156-6978","authenticated-orcid":false,"given":"Yok\u2010Lam","family":"Kwong","sequence":"additional","affiliation":[{"name":"Department of Medicine Queen Mary Hospital  Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"e_1_2_9_1_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"e_1_2_9_1_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-781989"},{"key":"e_1_2_9_1_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"e_1_2_9_1_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_2_9_1_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133"},{"key":"e_1_2_9_1_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"e_1_2_9_1_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"e_1_2_9_1_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12130"},{"key":"e_1_2_9_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13920"},{"key":"e_1_2_9_1_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2931-z"},{"key":"e_1_2_9_1_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3007-9"},{"key":"e_1_2_9_1_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_2_9_1_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_9_1_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"},{"key":"e_1_2_9_1_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.212"},{"key":"e_1_2_9_1_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03762-3"},{"key":"e_1_2_9_1_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03856-y"},{"key":"e_1_2_9_1_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000324"},{"key":"e_1_2_9_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"e_1_2_9_1_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"e_1_2_9_1_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-772673"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2787","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:10:54Z","timestamp":1781500254000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1002\/hon.2787"],"URL":"https:\/\/doi.org\/10.1002\/hon.2787","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2787\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2787\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2787\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2787\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2787\/v2\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"2020-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}